The global blood coagulants market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The rise in the prevalence of blood disorders such as hemophilia is anticipated to drive the growth of the global blood coagulants market. According to the data published by National Center for Biotechnology Information (NCBI) in 2021, hemophilia is a severe hereditary hemorrhagic disorder. Hemophilia is an inherited condition caused by a deficiency of clotting factors in the blood. The prevalence of hemophilia is approximately 1 in 10,000 live births and the number of people suffering from hemophilia is around 400,000 globally. Moreover, hemophilia A is more prevalent than hemophilia B. It presents in 1 in 5000 live male births, whereas, hemophilia B presents in 1 in 30,000 live male births.
In June 2019, Hemophilia Federation (India) (HFI), organized an initiative on Hemophilia Care- V in New Delhi. This program marked World Hemophilia Day which is held annually in April, over in 140 countries. This initiative is organized by HFI in collaboration with Ministry of Health & Family welfare. This initiative aimed to raise awareness about hemophilia and other inherited bleeding disorders which is expected to promote the market growth. Further , as per the Ministry of Health and Family Welfare, under the National Policy for treatment of rare diseases, the Government of India (GOI) is anticipated to set up a corpus fund with an initial amount of 100 crores towards the funding treatment of rare genetic diseases. Thus, such government initiatives are anticipated to drive the growth of the blood coagulants market globally.
Looking towards the demand for the blood coagulants, key market players are adopting various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in April 2020, Hema Biologics had received the USFDA approval of Sevenfact (coagulation factor VIIa (recombinant) for the treatment and control of bleeding episodes in adults and adolescents with 12 years of age with hemophilia A and B with inhibitors. Further, in February 2020, Novo Nordisk had announced the launch of Esperoct. It is a long-acting recombinant factor VIII product for the prevention and treatment of bleeding in individuals with hemophilia A.
In 2019, Novo Nordisk had received the USFDA approval of the biological license application for Esperoct. The approval was based on clinical trials designed to evaluate the safety and efficacy of the therapy in 270 previously treated patients with hemophilia A. In April 2019, Roche had announced the launch of Emicizumab in India for hemophilia A. It is indicated as a prophylactic treatment to reduce the frequency of bleeding episodes. Thus, such launches are anticipated to accelerate the growth of the global blood coagulants market during the forecast period.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Global Blood Coagulants Market at https://orionmarketreports.com/request-sample/?id=93765&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Bayer AG, Pfizer Inc, Novo Nordisk, and Octapharma among others.
A full report is available at: https://orionmarketreports.com/global-blood-coagulants-market/93765/
Global Blood Coagulants Market Report by Segment
By Type
- Recombinant Coagulation Factor
- Plasma Coagulation Factor
By Application
- Hospitals
- Pharmacy
- Others
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
